Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves superior HbA1c reduction (up to 2.6%) and weight loss (up to 15.7%) compared to other GLP-1 RAs and insulin, making it a highly effective treatment for T2D and obesity.
Tirzepatide is a once-weekly injection that targets both GLP-1 and GIP hormones. It is highly effective for lowering blood sugar (up to 2.6% HbA1c reduction) and promoting significant weight loss (up to 15.7%). It is more effective than many other GLP-1 RAs and insulin, making it a top-tier option for managing T2D and obesity, despite being an injection.
Tirzepatide (5, 10 and 15 mg doses) is the first dual GLP-1 and GIP RA approved for T2D and chronic weight management with up to 2.6% mean HbA1c reduction, 15.7% mean weight loss (WL) and good safety and tolerability profile.
Why this rating
Based on multiple Phase 3 SURPASS trials comparing it to other established treatments.
Source
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Prathima Gogineni et al. · Expert Opinion on Pharmacotherapy · 2024
DOI 10.1080/14656566.2024.2356254
More from this paper
- Oral semaglutide at 50 mg once daily achieves significantly greater HbA1c reduction (2.1%) and weight loss (9.8%) compared to the approved 14 mg dose, with higher discontinuation rates due to gastrointestinal adverse events.Good
- Orforglipron, an oral non-peptide GLP-1 receptor agonist, demonstrates efficacy comparable to injectable GLP-1 RAs with fewer dosing restrictions, achieving up to 2.10% HbA1c reduction and 9.6% weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →